Dr. John Cush RheumNow
6 years 1 month ago
Study of 4 refractory juvenile dermatomyositis (6-20yrs) treated with baricitinib (4–8 mg/day) Significant improvement noted by week 4 in global activity, skin scores, weakness but little change in muscle enzymes or calcinosis. Steroids/other meds lowered https://t.co/GKGBXrogEm
Dr. John Cush RheumNow
6 years 1 month ago
Non-Radiographic Axial Spondyloarthritis has Its Own Diagnostic Code; As of October 2020, nr-axSpA will be officially included in the 10th version of the International Classification of Diseases (ICD-10) coding manual as M46.8 https://t.co/AftIecuDqB https://t.co/uncIvUaqHV
Dr. John Cush RheumNow
6 years 1 month ago
Flexible polymers (PET) can be used for point-of-care diagnostics & analytics. A uric acid biosensor made to detect SUA in saliva, using PET, coated w/ uricase to detect UA; shows sensitivity, low detection limit, & wide linear range. Is this the future? https://t.co/fZP7HUpHfm
Significant variations were seen across hospitals in the treatment of children admitted with new-onset systemic juvenile idiopathic arthritis (JIA), despite increasing evidence of the efficacy of biologics and the hazards of extended glucocorticoid exposure, a retrospective cohort study found.
A longitudinal study of administrative data from British Columbia shows that nonsteroidal antiinflammatory drugs (NSAIDs) use increases the risk of cardiovascular disease (CVD) among osteoarthritis (OA) patients.
Dr. John Cush RheumNow
6 years 1 month ago
Metformin as cotherapy in RA? It lowers RA risk in animal models. >2500mg/d lowers risk incident RA in women. Japanese study shows it suppresses osteoclastogenesis and upregulation of inflammatory cytokines, protease and growth factor genes. https://t.co/UEDMgtqLZG
Dr. John Cush RheumNow
6 years 1 month ago
Successful treatment of refractory palmoplantar psoriasis in a psoriatic arthritis patient with the JAK inhibitor tofacitinib https://t.co/bdhppoUkmz
Dr. John Cush RheumNow
6 years 1 month ago
President Trump took HCQ/Azithromycin.... Lancet Rheumatology reports that HCQ in RA has no cardiac risk but long term HCQ increases risk cardiovascular mortality, that may be further augmented by azithromycin. https://t.co/JRtkkAuEeu
Among patients with systemic lupus erythematosus (SLE), cancer risks overall were associated with older age at diagnosis and male sex, and lung cancer specifically was related to smoking, analysis of data from a large multicenter cohort found.
Dr. John Cush RheumNow
6 years 1 month ago
Study of 1,631 incident RA & 3283 controls shows respiratory disease assoc with risk of RA, irrespective of RF & CCP and mostly in nonsmokers. aOR increased for chronic upper (1.4), acute lower (2.4) & chronic lower (1.6) Resp Dz, stronger for ACPA/RF+ https://t.co/C1hA631PIW
Dr. John Cush RheumNow
6 years 1 month ago
Stanford grows new cartilage in mice OA knees using resident skeletal stem-cells generated using microfracture (MF) surgery. MF-activated SSCs Rx w/ BMP2 and soluble VEGFR1 skewed differentiation toward articular cartilage. https://t.co/dkr1vgU9CF https://t.co/WpKpaDG2qf https://t.co/vi4VGqn0U0
Dr. John Cush RheumNow
6 years 1 month ago
Mayo case controlled study of 212 autoimmune pts - half w/ CNS inflamm dz and half without. TNF inhibitor use was associated with an increased risk of inflammatory CNS dz (adj OR, 3.01; 1.55-5.82; P = .001); most of these occurred in RA pts (aOR, 4.82) https://t.co/8TsYxDhUZx
Dr. John Cush RheumNow
6 years 1 month ago
Fibromyalgia & Exercise? Systematic review of 50 trials, shows that, compared to usual care, exercise had moderate effect on fatigue, small effect on sleep and meditative exercise programs were the most effective for improving sleep quality. https://t.co/iloD8rMx64
JAMA has published a clinical update of recent studies on GCA. While PET/CT scanning are novel means of demonstrating activity, they have not changed the diagnostic approach to GCA or PMR and although there are no new proven treatment strategies for PMR beyond glucocorticoids, the FDA has approved tocilizumab as a first-line glucocorticoid-sparing agent.
Dr. John Cush RheumNow
6 years 1 month ago
Responses to switching TNFi in SpA go down w/ the 2nd TNFi. 1st TNFi @ 3 mos ASAS CII 51%; 2nd TNFi 41%; BASDAI @6 mo, 1st 46%, 2nd TNFi 33%. Compared to primary failure, pts w/ 2nd failure (OR 7.3 ) or toxicity (OR 9.1) had better ASDAS-I https://t.co/jMCUfBtxmY https://t.co/PBkQNOwVRQ

